Scientists test Triple-Threat attack on Tough-to-Treat blood cancer
NCT ID NCT05260957
Summary
This study is testing a new combination treatment for aggressive non-Hodgkin lymphoma that has returned or not responded to standard therapies. It will give 22 patients a three-part regimen: first a personalized cell therapy (CAR-T), followed by two other drugs. The main goal is to see if this approach can completely eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.